Cipla's Lenalidomide capsules are therapeutic equivalent generic version of Bristol Myers Squibb's Revlimid capsules Drug firm Cipla on Wednesday said it has received approval from the US health regulator for Lenalidomide capsule, a drug used to treat various types of cancer. The company has received the final approval from the US Food and Drug Administration for the product in strengths of 5 mg, 10 mg, 15 mg and 25 mg, Cipla said in a regulatory filing. Cipla's Lenalidomide capsules are therapeutic equivalent generic version of Bristol Myers Squibb's Revlimid (Lenalidomide) capsules. Lenalidomide is an immunomodulatory prescription drug indicated for several hematological malignancies in adults such as multiple myeloma, myelodysplastic syndromes, mantle cell lymphoma, follicular lymphoma, and marginal zone lymphoma. Depending on the type of cancer, it can be used as monotherapy or combination as a part of first line regimen, maintenance regimen or relapsed settings, (IMS Health), Revlimid capsules had sales of around USD 2.58 billion in the US for the 12-month period ended June 2022. The product will be available for shipping soon
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!